Stocks Wrap Up A Positive Week.. And How Pharma Will Fare Under Tariffs 4/25/25

25 Apr 2025 · 43 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" Episode Title: Stocks Wrap Up A Positive Week.. And How Pharma Will Fare Under Tariffs (4/25/25)

Overview In this episode of "Fast Money," hosted by Melissa Lee, the roundtable of expert traders discusses the positive stock market trends, particularly in tech, and the implications of tariffs on the pharmaceutical industry. The episode provides actionable insights for investors as major companies prepare to report earnings.

Key Highlights

  • Market Performance:
  • The Nasdaq index increased by nearly 7% over the week.
  • S&P 500 and Dow also showed gains, indicating a market recovery.
  • Tariff negotiations appear to calm investor concerns.
  • Upcoming Earnings Reports:
  • Major companies such as Apple, Microsoft, Amazon, and Meta are set to report earnings, influencing market momentum.
  • Concerns remain whether these reports will sustain the current market gains.
  • Tech Sector Analysis:
  • Google’s recent performance suggests confidence in the AI sector, despite ongoing regulatory issues.
  • The traders express a mix of optimism and caution regarding upcoming earnings, specifically referencing the tech giants.

Key Discussions

  1. Impact of Tariffs on Pharma:
  2. A $51 billion tariff could increase U.S. drug costs by approximately 13%.
  3. Discussed the potential for a research renaissance in pharmaceuticals despite tariff concerns, citing significant advancements in drug development.
  1. Market Dynamics:
  2. Traders noted an increase in volatility and uncertainty, with discussions around potential recession impacts and consumer sentiment.
  3. The traders are observing the balance between inflationary pressures and growth opportunities in both tech and pharma sectors.
  1. Apple's Manufacturing Shift:
  2. Apple is considering moving iPhone manufacturing to India to mitigate tariffs, but analysts question the viability of this strategy.
  3. Concerns about demand and market share in China, especially against growing local competition, were raised.
  1. Tesla and Self-Driving Technology:
  2. Tesla shares rose significantly following news of relaxed self-driving regulations.
  3. Discussion on the implications of potential robo-taxi services and the impact on Tesla's market position.
  1. Bitcoin's Resurgence:
  2. Bitcoin experienced a notable increase in value, prompting discussions about its position as a hedge against inflation.

Expert Opinions

  • Craig Moffitt (Analyst, Moffitt Nathanson): Expressed concerns about Apple’s valuation amidst tariff uncertainties, emphasizing demand issues in China.
  • Len Yaffe (Managing Director, Kess of Capital Management): Highlighted opportunities in pharma despite tariff implications, discussing various stocks with potential growth.

Tactical Insights

  • Market Positioning: Traders suggest maintaining a balanced portfolio with a focus on sectors showing resilience amidst volatility.
  • Investment Strategies: Emphasize the importance of firm fundamentals and long-term growth potential, especially in tech and pharma.

Final Thoughts The episode concludes with a mixed outlook on the market, urging investors to remain vigilant as earnings reports loom. The traders encourage a focus on quality investments and careful consideration of market dynamics influenced by tariffs and consumer sentiment.

Key Takeaways

  • Markets showed positive momentum due to tech recovery and calming tariff negotiations.
  • Upcoming earnings from major tech companies are critical to sustaining market gains.
  • The pharmaceutical sector may face challenges but also shows potential for growth through innovative advancements.
  • Investor sentiment remains cautious amidst discussions of tariffs and economic uncertainty.

For more insights and detailed trading strategies, tune in to "Fast Money" airing weeknights at 5 PM ET on CNBC.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Live from the Nasdaq market site in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. Tech on the rebound. The Nasdaq popping over 6 percent this week. The S &P climbing more than four. But with Apple, Amazon, Microsoft, Meta and more reporting next week. And the good vibes last. We'll debate that. Plus, self-driving surge shares of Tesla popping. As the Trump administration says, it will loosen rules to help automakers take on China in the race for a driverless future. And later, is Apple's expansion to India going to happen? One street bear isn't buying it.

0:30A big week for Bitcoin. What's behind this comeback? And how are the president's tariffs impacting one of TV's biggest advertisers? We'll go inside the numbers. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Fireman, Courtney Garcia, and Steve Grasso. We're all wearing it tonight. So amazingly color-coordinated tonight. This is not coordinated. This wasn't done on purpose. Happenstance. We start off with a tech-led rally on Wall Street. The NASDAQ jumping another percent today, bringing its gains for the week to nearly 7%. And get this, the index is now positive in April, putting it on pace to break a two-month losing streak.

1:04It has now rebounded more than 17 % off its 52-week low hit three weeks ago. The S &P and Dow also finishing in the green, clawing their way back from early in the session losses as tariff negotiations seem to be quieting some investor concerns. But the next big test for markets is just around the corner. Some$10 trillion worth of companies are reporting next week, headlined by Apple, Microsoft, Amazon and Meta. So will next week's reports keep the momentum going, or are we in for a rude awakening? Well, if there were any concerns, Google certainly, for at least now, said everything's going to be all right, at least when it comes to the AI trade.

1:38Yeah, I mean, I thought I listened to the call this morning, and I thought it was pretty good. I think Dieter talked last night about for the cloud part is being, you know, supply constrained, not demand constrained. So that was good. But we have this huge question mark about, you know, what's going to happen with the breakup or not or any of that. And then also, this was the first quarter. And so we don't have any sense of what this next quarter brings. So we'll have some information for sure, but it is possible that we have sort of, you know, conservative outlooks or no guidance or things like that.

2:11Or maybe the, you know, the dual guidance, tariff this, if not that. So, I mean, it's we're coming off a better place, but things have rallied so much that I'm a little bit concerned the bar is high now. I think in Meta and Amazon, to some extent, we have companies that, look, Amazon can tell you a lot about what they might be seeing in terms of the consumer and possibly some tariff dynamics. But I think Apple's really that tell. And I think we're at least going to hear from Apple. But going into those numbers, this is the market that's now rallied 14.5 % off the intraday lows on April 7th. Although, you know, we're only about one and a quarter percent higher than where we closed on the day of, oh, We've got a 90-day reprieve on April 9th.

2:57So the market's done a lot in between. And if you think about it, I just what's I think very encouraging for the market is that over the last couple of days, that downtrend, that downtrend in the S &P, in the NASDAQ and in the semiconductors has been broken today and even yesterday. And if you look at semis, I would argue that the NASDAQ Wednesday, Thursday, Friday is through that downtrend. So some of this price action, I'm sure chart folks out there will tell you, you've actually started to create some real positive momentum to the upside. Back to the earnings, I do think Meta was the stock that couldn't do anything wrong until suddenly they got kind of caught up in the middle of this.

3:33And really the questions about what CapEx spent meant. We can't wait to hear more about that. But everything we've heard so far, no delay in CapEx. Demand is fine. If you look at all the charts, they all fell off a cliff right around deep seek. That was the initial sell-off in the whole space. I think even though they bounced, to everyone's point, they bounced off the recent lows, they're still off that high from when that DeepSeek headline really hit the tape so substantially that these stocks really have room to move forward. We've seen not a substantive bottom because we don't know yet, but you trade below 5 ,000.

4:10I don't think we're going to revisit that anytime soon. and the 10-year, I think, has more control over the overall markets than anything else. And we've seen the Trump administration be really sensitive when that yield spikes. I think they're going to come out of the woodwork. They're going to do anything that they can to make sure that yields stay low. They like low rates. It's no secret. And I think the pivotal point of this week was when Governor Waller came out and said on another news station, came out and said that if the jobs market starts to fall off a cliff, there'll be more cuts and there'll be quicker than people think there's going to be.

4:49So I think it put back on that Fed put where that Fed put was probably not in existence until this week again in earnest. So a couple of things, a couple of puts are back in play then. There's a Trump put, which everybody thought was going to be low, low, low. But then he comes out with very market friendly tones when it comes to describing talks with China specifically. And then there's a Fed put that's also back on the table this week. These are two monumental developments for investors. Yeah, and I think that's where you're starting to see the shock of the tariffs. People are really starting to move past that, and they're really starting to see, can the markets really get past the facts of the tariffs, the facts of the uncertainty, and really look into what's moving forward?

5:27Because before the tariffs, there was a lot of optimism with less regulation, tax-friendliness, just in general, a pro-business-friendly environment. I think at some point, you're going to start to get back there, and that's where people are starting to look at the AI story and saying, we can't forget about this, and there likely is going to be a place where this makes sense again. So I think the fact that the markets got so low, the volatility hitting those levels, the consumer selling the way that they were, I think we're starting to see past that. And I think weeks like this are a very optimistic sign.

5:53I think you could probably make the case, too, that we have hit peak uncertainty when it comes to tariffs and that anything that develops now is only going to be a positive. It's got to be a positive. I think that's a good way. It's certainly the way they want to portray it. And I believe that's the way it is. Right. They they're desperate to and working, you know, 24 seven probably to get some deals. That would be good. I think that, yeah, the sort of abyss of the Liberation Day tariff regime, you know, schedule. I think that they've really pulled back very far from that as they needed to. But maybe I mean, I guess I can agree with the uncertainty, maybe peak on tariffs because we've we've looked into the abyss.

6:36But we certainly have peak, I think, uncertainty in terms of market multiple. Where are we supposed to trade? Lack of visibility for companies into their core business. Scenario analysis upon earnings releases. This is not what you want as an investor. I don't need three scenarios for a CFO to tell me what their business could do. I want them to tell me what they think their business is going to do and make a call. I know Karen doesn't believe in guidance anymore. I never believed in guidance, but I really don't believe in it now. Right. So but I think the uncertainty for the markets is truly the uncertainty that's out there for the economy and where these stocks should trade.

7:08And if you think of a world post covid, I won't go all the way back to the financial crisis where we had tons of accommodation, but we threw 25 percent of GDP at the problem. It was a war economy. It was all kinds of things. It was fiscal nausea. It was central bank nausea. I think a lot of us would agree. It's great that we're tightening the belt and have been. But what does it mean for equities? I'm not sure 21, 22, 23 times forward on the S &P is where we're supposed to be. By the way, I kind of like the two scenarios. I didn't at first. And now I'm sort of leaning towards that. If a CEO gives you this is worst case scenario, this is best case scenario.

7:42I mean, look at analysts, right? You have your base case. You have your bull case. You have your bear case. So there is something to a CEO saying, here's my bear case. Here's my base case. This is what I'm looking at now if nothing changes. And here's the worst case scenario to invest around. I always thought analysts who gave three scenarios was like CYA case. You got every scenario. Well, that may be as well. You can understand it, though. But I mean, I agree. I mean, let's say, oh, well, if my cost of goods is actually 40 percent higher than I thought, well, then this, you know. But one of the things, the VIX, though, has come down a lot.

8:19It's not quite where it was just before Liberation Day, but at 20, just under 25, it's starting to come down to like, all right, this crisis passed. But I think it's sort of getting time to look at protection that was way too expensive with the VIX. But as an investor, are you going to invest behind a CEO that gives you three scenarios? Are you going to invest behind a CEO that gives you a scenario and says, this is where my business is good or bad? So it just gets back to the markets. And we can assess really where the selling has come from. I said yesterday, I think a lot of the selling really has been hedge funds, then de-risking, followed by CTAs.

8:55I don't think retail has done a whole lot here. And I don't think foreigners have done a whole lot here. But ultimately, it gets to a place where where is new money going to be allocated? If you look at the biggest investors in the world, pension funds, endowments, I'm not sure they feel comfortable to be allocating new money here. And my guess is they can wait, and they can wait another earnings season if they have to. Well, one of the biggies reporting next week is Apple, and it is reportedly planning to move manufacturing of U.S.-sold iPhones to India as soon as next year to avoid tariffs on China.

9:22But the street's biggest Apple bear suggests the goal is unrealistic. Moffitt Nathanson writing in a note to clients today that a global trade war is a two-front battle, impacting costs and sales. Moving assembly to India might, emphasis on might, help the former. The latter may ultimately be the bigger issue. Craig Moffitt, who's got a sell rating on Apple, is behind the note. He is the firm's partner and senior managing director. Craig, always great to see you. You've had a great call on Apple. That sell rating was put on a stock back in January. You leaned in again when you lowered the price target and lowered estimates as well.

9:54So at this point, what is the bigot? There's a myriad of issues. It could be tariff uncertainty. It could be brand or American brand damage, Apple brand damage. What is the biggest issue here for the stock? Hi, Melissa. First, I don't think of myself as the biggest Apple bear. I actually think quite highly of Apple. My concern about Apple has been the valuation more than the company. But I would say to your question, the answer is sort of all of the above, right? You have a tremendous sort of menu of problems created by tariffs, and moving to India doesn't solve all the problems. Now, granted, it helps to some degree.

10:38By the way, I would sort of question how that's going to work if the glass and the

10:52fill of materials for the entire phone is manufactured in China, and yet it's assembled in India. It's not entirely clear how that, to the extent to which that will avoid Chinese tariffs. So there's still some questions about that. But even if you do that, what you were raising is a series of questions about the demand side that is created by a tariff war. And in a trade war, it's not just the cost of goods. It's also the demand that suffers. Right. Also, you know, the companies actually that would manufacture the phones in India, one of them is still Foxconn. So they could still have pressure from the Chinese government, even if producing in China.

11:37I'm wondering, though, you know, when it comes to this sort of demand issue, you know, in China, one could argue that Apple was already starting to lose that battle in terms of losing market share to local brands. And this sort of trade war could actually accelerate sort of the backlash against Apple. And then you add to that all of those people out there who in China who are upgrading to AI enabled phones there who are out of the Apple ecosystem potentially permanently. How do you view that market share loss? Because it's not just the numbers here and now, but there seems that there would be a knock on effect going into the future of those lost customers.

12:15You're right, Melissa. It's a very real problem, right? During the first quarter, we've seen declines or we expect we'll see declines of something like 8 % in China. But that's against a backdrop of some pretty significant handset subsidies. And the volumes are really going to the Huawei's and the Vivo's and the local competitors in China rather than to Apple. Some of that is because of the price point. The subsidies were aimed at lower price phones. But some of it is that kind of nationalism that is viewed as patriotic in China to buy a Chinese-made phone and a Chinese-branded phone. And that exactly, as you say, means those people won't be inside the Apple ecosystem and won't be generating revenues two, three, four, five years from now.

13:08Hey, Craig, it's Tim. I guess I'd like to talk a little bit also about post-DeepSeek. This was seen as kind of a net positive for, you know, for Apple, because maybe there's a lot. There certainly could be a movement to handsets a lot faster. There's the universal conviction or view that the Apple intelligence has been a big nothing, but it wasn't priced into the stock. So I'm just trying to understand how you view. I still ultimately believe Apple's power is that installed base and that it will be the way AI is served up to many people. And they will need to refresh at some point. Can you kind of lay this out?

13:41Yeah, thanks, Tim. You know, you can see it either way, right? I mean, on the one hand, when DeepSeat came along, it did endorse the model of, if you'll forgive the pun, of smaller models on handsets. On the other hand, remember that the enthusiasm for Apple is primarily based on the idea that an AI solution on the handset is going to require substantially more memory and a more powerful processor. DeepSeek raised some questions about whether that's going to be the case. And remember, we've said all along that if you're going to underwrite an upgrade cycle in your multiple for Apple, it can't be a one-time upgrade cycle.

14:28It has to be a permanent acceleration in the rate at which people upgrade their phones. DeepSeek, I think, raises some real questions about how much that's going to be required and how much can be done with small language models instead of large language models. It's Karen. Thanks for being on, Craig. Let me just ask you, so you have this$141 price target. What are the pieces that got you to that$141 valuation? Well, so it's a couple of things. First, I think you have to, we wrote about in our report, you first have to acknowledge that with interest rates higher and with a higher equity risk premium, a slightly lower multiple for the whole market, by the way, is warranted.

15:12I heard Tim talking about that before I came on. I think that's exactly right. You have to question the multiple. So we've trimmed our multiple a little bit, but we've also trimmed our estimates. So, you know, you have about a$300 billion product business at Apple, aside from services. Let's say there's a$60 billion or so cost of goods sold there. Depending on what the tariff level of that, you have$20 billion. Now, that might be an increase in cost that's absorbed to some extent by the suppliers, to some extent by Apple itself, or to some extent by consumers. But you also have the demand destruction that's created by potentially higher prices.

16:00Remember, you had AT &T, Verizon, and T-Mobile all this week come out and say, we're not going to underwrite the additional cost of tariff handsets. The consumer's going to have to pay for that. So you're going to have some demand destruction that's going to show up in even longer holding periods and slower upgrade rates, all of which probably trends estimates. Next year consensus for the full year is about$7 or about$8, I mean. We cut that down in our model to about seven. And with a small cut to the multiple, you're talking about a warranted value that's probably in the 140 range. And again, none of this is because Apple is a bad company.

16:48They still have a great balance sheet, a great consumer franchise. It's just the reality of there are no good answers when you are a product company and your products are going to be significantly tariffed and you're heading into a market that is likely to have at least some deceleration in consumer demand because of the macro economy. Great. Great to speak with you. Thanks for joining us. My pleasure. Good to see you. Craig Moffitt with Accelerating on Apple. We've got a news alert. Former Fed Governor Kevin Warsh making comments about the relationship between the central bank and the Treasury.

17:21Eamon Javers has got the details on this one. Eamon. Hey there, Melissa. This coming from Reuters reporting of a Kevin Warsh speech at a conference here in D.C. earlier today. This is interesting because of the timing of all this in the context of President Trump's criticism of Jay Powell and these questions of will he or won't he in terms of attempting to fire Jay Powell. Kevin Warsh at this conference, very critical of the Fed, saying that he believes in the operational independence of the Fed. According to Reuters, Warsh told a conference today that the Fed has gone beyond its remit and undermined its own claims to independence.

17:58He urged the Fed to stop relying on data dependence to guide its decisions. And he blamed the central bank for aiding the expansion of the U.S. national debt and for allowing inflation to surge after the pandemic. So this is similar in tone, Melissa, to some of the criticisms that Warsh has made before. But the whole context here is that Warsh is seen by a lot of folks as the potential Trump nominee for Fed chair at some point after Jay Powell's term is over next year, or if something happens between now and then, more immediately than that. And so the question here is, is Kevin Warsh making these comments because these are his standard criticisms of the Fed, or is he making these comments now because he's sort of lobbying for the job?

18:42One big asterisk to all this, although there has been a lot of discussion about whether Trump will or will not try to fire Jay Powell before his term is up next year. I asked the president in the Oval Office earlier this week if he believes he has the power to fire Jay Powell. And the president said, I don't want to even get into that because I have no intention of firing Jay Powell. So the current line from the White House is the president doesn't intend to fire Powell. But clearly, Warsh is the man in the wings. And so a lot of attention being paid to what he has to say. I mean, it does sound like an audition for a job, Eamon.

19:17In terms of not relying on data dependence, has he said either in these comments or in past comments what then the Fed should rely on? Because if it's not data. Boy, I wish we had Steve Leisman here for this because he has an encyclopedia of all the Fed speakers and we're a little bit out of my area of expertise. But yeah, I mean, he has been critical of the Fed before on these issues of U.S. debt and the policy post-pandemic. And then the question is, is he doing this just because, look, there's a lot of finance ministers in Washington this week. The IMF is here. There are a lot of folks making speeches at a lot of conferences in financial Washington this week.

20:01or is this timed to sort of dovetail with the president's criticisms of J-PAL? And so that political timing, I think, is the thing that's going to raise a lot of eyebrows. I'm just too used to you having all the answers, Eamon. I didn't mean to put you on the spot. Eamon, thank you as always. Get Steve on the line. He's the expert. All right. Eamon Javers reporting from Washington. What would we make of a Fed chair, Kevin Warsh? Yeah, I think he's for lower rates. And I think what Warsh had said was not solely on data, not solely on the data points that the Fed is worried about market valuations, worried about asset prices, include those all in, not just data dependency.

20:46So I think, you know, to be to be not fair to him, but I think that's what his view is. And obviously he would toe the line for the administration. And you said this sounds like an audition. We already know who's going to be the next. He'll be the next Fed chair when it happens. So, I mean, I think he would be, you know, he's a very good choice, I think. He's a very smart guy. I think what happened, though, the last time that the Fed ignored data and thought things were transitory, right, instead of ignoring that data and saying, well, it's not going to be like that. Right. That ended up being an enormous mistake.

21:21And so you can understand why they would be hesitant to do that again. Right. And I think, too, when it comes to the Fed, we saw this back in the fall where they started lowering rates, but the bond market just did the opposite. And I think to a certain extent, we can see those policy changes, but the markets are also going to do something different. I think that is something we want to continue to watch is what are the bond markets telling us? Because that's been much more indicative, especially over the last six months of where things are going. And so that's what I would continue to watch, especially with all this arguing on Capitol Hill right now.

21:48But what was interesting about just what we went through here with Eamon is that these headlines seem to be coming out in the context also of the Treasury. I didn't really understand what those headlines were saying, because, again, the independents, obviously, the Treasury and the Federal Reserve, very, very different functions. But obviously, the Treasury certainly has there's there's a lot of interplay ultimately what the Treasury is doing based upon what the Fed does. The other confusion really could be with headlines to talk about data dependence. And all we've been doing is talking about an independent Fed.

22:17and ultimately what is the Fed going to make their decisions based upon. And there's been some concern that some of the folks that are compiling a lot of the data and some of these independent sources that actually are this is what they do are no longer doing what they do because they've actually been cut loose. So, I mean, there's different dynamics here. I agree with what everybody here is saying is Kevin Warsh, I think, brings a lot of continuity. And I think most people are not concerned about that. But that these headlines are such that I do think it's easy to make some headlines here. Coming up, Tesla shares revving to their best week since November as federal regulators loosen self-driving rules.

22:54The deregulation details next. Plus, we're searching for gains in Google where the stock may find its next leg higher after last night's earnings right after this. Welcome back to Fast Money. Tesla shares surging nearly 10 percent today, locking in their best week since the election. The latest pop coming on hopes of deregulation of full self-driving technology that will prompt faster rollout of its robo-taxis. Meantime, Alphabet managing to close a percent and a half higher on the back of yesterday's results. Alphabet saying Waymo, its self-driving taxi company, may offer cars for personal ownership in the future.

23:27They also reported an astronomical rise in the number of rides that they are offering over a year ago, which should—I mean, you discussed this last night, Tim. It should impute some value to Google. I don't think I mean, again, I'm not a Google analyst and I don't have my sum of the parts in front of me. But but I can tell you that it's not getting 30 to 50 billion in valuation or maybe, you know, maybe that's where it is. But again, think about where RoboTaxi is for Tesla. So I just I get back to those numbers on Google. I think it was an exhale. I think it was a relief. And I think the more important parts of the business were fine.

24:00And I'm not ready to say goodbye to their core search business. And I think when it comes to Tesla, they were down over 50 percent off of their highs before this week. And now you're seeing that Elon is maybe stepping back into the Tesla role, which people are happy about. But this news with less regulation, that's the reason the stock popped so much post-election. It's still down more than 40 percent from its highs. So I think it still has some ways to go there. But I think this is a bigger picture for the overall markets, where if we are going to start to actually see this less regulation and get past these tariffs, you can see how much the markets want to see that.

Read the full transcript

24:29And they will put a price to that. So I think that's that's an optimistic sign. Yeah, I think if if this happens in June and they go to RoboTaxi, you're going to see this pop today is probably nothing compared what you could see come June if it actually rolls out, because we've seen this so many times before. Don't you have just seen that RoboTaxi makes money? I think the fact that it actually starts is you can start. You can start getting to efficiencies. I think the stock could be up 30 % to 50 % higher than where it is now if it actually – you start to see that rollout. But again, you may be right on that because that's how Tesla is traded.

25:08But that's, again, the same mentality where you're buying on the come, which ultimately – discounted cash flows. You can do anything you want with a DCF model. You could make Google$1 ,000 a share. And I think the futurists would like to do that. But, I mean, I think you've got a case here where I can't just because they start with RoboTaxi imputing that everybody that buys a Tesla is going to loan it out and it's going to be 100 ,000 pays back 75 or whatever that math was. It's been so long in coming, though, that you actually get there. But Tesla demand is down, right? I mean, we talked about the brand.

25:39Right. But it would be interesting. That could happen. Let's say they announce it and it wouldn't be surprised at all if the stock, you know, is up a lot. But the irony, I think, would be I could see Google trading down maybe on that because like, oh, all right, Waymo is not worth as much now. Even though they don't assign a big valuation to Waymo, which I think it should get way more than what I think is in there. That could happen as well. Coming up,$51 billion. That is how much tariffs could increase drug costs in the U.S. But our next guest says we are in a research renaissance that could keep the pharma industry humming right along.

26:13The future of this space next. You're watching Fast Money Live from the NASDAQ MarketSite in Times Square. Back right after this. Welcome back. We wanted to introduce CNBC's newest subscription streaming product, CNBC +, where you can stream Fast Money and any of your other favorite CNBC shows anytime, anywhere, on the go and also on demand. What you're seeing on your screen today is our CNBC Plus data feed, which displays an enhanced data view and the latest headlines during our live business news lineup. So check it out. Meantime, tech leading the market as stocks wrap up a big week of gains.

26:43The Nasdaq jumping one and a quarter percent, up nearly seven percent on the week, moving into positive territory for the month. The S &P gaining three quarters of a percent, its fourth straight winning day, and the Dow up just slightly, finishing the week up more than two percent. Meantime, T-Mobile headed in the opposite direction, down more than 11 percent today, its worst day since 2011. The company posting disappointing wireless subscriber numbers in yesterday's earnings report. And Boston Beer getting a boost despite warning investors that tariffs could hurt full year results. The same Adams maker handily beating Wall Street's top and bottom line estimates for Q1.

27:15Finally, Bitcoin surging more than 12 percent this week, crossing above this$95 ,000 mark today for the first time since early March. What did you make of the Bitcoin move? Well, long Bitcoin. I thought it was interesting. I mean, there were some, you know, talk of Trump related products. There's that. But there was also sort of the for the same reason that gold has been very strong. Bitcoin is as well. So I'm hanging on to it now. I sort of think it gets to the point of a gravitational pull towards 100. Yeah. And I think the interesting thing is that gold and Bitcoin have been following that same path.

27:52But gold is starting to run out of steam, maybe momentarily or short term. But Bitcoin kept rising. So we got down to that mid-70s number. And then when you follow the retracement from 109 down to 70s, 75 or so, you capture the 50 % and the 618 % at 92 to 97 ,000. That's where the sellers come in. So that's called the bounce level. So the 50 and the 618 on a retracement to get a little inside the huddle. And that's where the sellers will come in. If it could bounce above 97 ,000, that's true momentum. And that's where you actually buy. But right now you want to see if it could bounce out of that zone.

28:31By the way, if you're in the Huddle, our team colors are powder blue. So just everybody knows that's what we're wearing today on the uniform. Coming up, big pharma's big problem. The$51 billion tariff question that could force some major changes in the industry. And why our next guest says there are still great deals to be had in the space. Welcome back to Fast Money. A 25 % tariff on pharma could add$51 billion a year to U.S. drug costs, according to an industry trade group report obtained by Reuters. That would translate to a near 13 percent hike in drug prices. But despite the potential sector overhang, our next guest says we're in a pharma stock pickers market.

29:07Let's bring in Len Yaffe, managing director at Kess of Capital Management. Len, great to see you. You list some stocks that you say are compelling, even despite the tariff overhang. Pfizer is one of them, and you could have made that case for a long time. So I'm just wondering how you view what value is right now. Sure. And there are two known unknowns, and those are the tariffs and whether or not we'll go to major pricing changes as it relates to favored nations with the EU. And I've grouped the large cap pharmaceutical stocks into three areas. I look at the companies that are dividend plays, which maybe don't have great pipelines or have patent expiry exposure.

29:53We're about to go through a very significant patent expiration cycle,$200 billion over the next five years. Those three companies are Merck, Pfizer and Bristol. Pfizer is a dividend play. It's boring. I don't think the pipeline is that great, but it's a 7.5 % yield. I then look at the companies trading between 13 and 15 times earnings. Those would be AbbVie, Roche, AstraZeneca, Novartis, Novo. And several of those companies have good growth drivers, as well as they have very impressive drugs in their pipeline. I think those stocks could be considered. And then lastly, there's King Lily, which I think is the best positioned pharmaceutical company that there is for many years.

30:37Trades at a multiple 34 times, but probably growing at 28 percent. And I think the estimates will have to be raised by Wall Street. So the two unknowns are difficult. They're partly factored into the stock prices. We don't know to what extent. I'm very confused by the commentaries that relates to tariffs in terms of what the endgame actually is. But within that, I see a very exciting what I've called a research renaissance for the drug industry. We're in several therapeutic categories. We're making incredible advances that will cure or make chronic several cancers. tremendous advances we talked about with GLP-1s, as well as advances in immunology, and a very overlooked area, kidney disease, there are several very exciting drugs.

31:30So I think the overriding fundamentals are great. The two unknowns do make it much more difficult. The research renaissance that you're talking about, is this causing you to invest in smaller biotech companies as opposed to pharma? I mean, do you see that as potentially the better play here. And you would have to assume that these smaller companies will either get taken out or they're well-funded, because in this environment, they're not going to be raising money, I would imagine. No, that's the great question. And in 21, companies went public at ridiculous valuations. Just real quickly,$750 million market caps with preclinical data, and it was going to end badly.

32:12It did. Now, many of those companies that made it through that cycle or have gone public more recently, are trading near cash valuations. And yet, in some cases, I think the compounds are very exciting. There's one small company that's got a market cap of$200 million. They're going to come out with a drug that looks very promising for polycystic kidney disease. We'll have other drugs in kidney, like IG nephropathy from companies like Vertex, a larger company. And because these companies raised money after they went public or when they went public, they raised sufficient funds, to your point, they have enough money to get through 27 for the most part.

32:56Those are the ones I'm looking at, which will be much later than the major data readouts we'll get over the next 18 months. All right. Len, great to speak with you. Thanks for your time and analysis. Oh, may I give a quick shutout? Okay. I'd like to wish a very happy birthday to my wonderful wife, Ruth. Thanks so much. Okay. Nice. Good. All right. Len, thank you. And happy birthday, Ruth. Karen, Avi reported and it was better than expected. Yeah, it was. And they also are viewed as sort of a little bit more insulated from tariffs. Yeah. I mean, there was a general bounce today, right? I think, you know, maybe just investors coming to market just seeming a little calmer.

33:35The whole tariff thing seeming a little calmer. Still, my biggest bet here is Lilly. Yeah, and this is an interesting segment here because typically this is something that's viewed as defensive and something that would benefit in the case of going into recession. But this is a case where it's the tariffs that are causing the potential increase of recession, in which case they are at face of. So I think you're really seeing that get priced in here. But I do think it's absolutely worth looking at some of these as an opportunity. Even some of these that are less exciting names than your Lilies, they are trading at really low valuations.

34:06They pay a good dividend. Even Lilly, which is pretty expensive after their trials recently, I think has a lot of optimism here. So I would actually take a look at this sector. Your Pfizer is, you know, dividend 7 percent. It's down 13 percent, though, for the year. Seven and a half. Seven and a half. Even more. It's down smaller every day. When you're talking about a really chunky div, that's Tim's Pfizer we're talking about. I'm in there with you. It's Karen's Pfizer, too. Bristol-Myers is also interesting here, too. And again, they just recently had Q1 numbers. They weren't bad. There was a couple, you know, they were more or less in line.

34:35Yes, exactly. The schizophrenia. So that's, I think, one that we had seen really picking up and closing the gap after a significant underperformance in 23-24, but has now fallen almost 22 % in the last month, month and a half, and I think it's interesting. Coming up, automakers hitting the gas on ad spending, how the industry is shifting gears in an attempt to get ahead of tariffs. More Fast Money in two. Welcome back to Fast Money. Automakers are some of the biggest ad spenders out there, and recent tariff pressures are forcing them to tweak their messaging and strategy. Julia Borson's got the details on how the industry is shifting gears.

35:12Julia. Well, Melissa, companies and sectors ranging from travel and beauty to mattresses and autos are marketing to consumers to buy now before tariffs drive up prices. Automakers have been tweaking their messaging and it is very visible because they're spending accounts for 7.6 % of all U.S. ad dollars and nearly 15 percent of all digital ad growth. Ford and Hyundai are promoting that they've temporarily locked in prices to reassure customers, and Nissan is promoting discounted prices, while Ford and Stellantis ads tout their American heritage. Global automotive lead at agency MRM Michael Jobst tells us, in the short term, they're using these tariffs as a buy now messaging opportunity to drive sales by heightening urgency.

35:56The goal is to pull forward as many sales as possible and sell through the existing inventory. He and other industry insiders tell us some ad spending from the second half of the year is likely getting pulled into this quarter. And another impact of this uncertainty, we can expect negotiations over upfront ad sales commitments to drag on for longer than usual as brands wait for clarity and potentially we could see fewer ad dollars committed upfront as brands look for flexibility. Melissa? Julia, thank you. Julia Boorstin. And, of course, this is really going to come into issue next week. We're getting reports from Meta.

36:32We heard that ad demand was very strong from Google. Financial services was one they pointed out a lot, and also the Timu Shien being down, which we'll hear. But, I mean, this is interesting. If it is pulled forward, then you don't want to put a multiple on that. Right. Right? But I don't know. I'm optimistic for Meta. I thought Google was very good. Can I go to Ford and GM off of that? Sure. So for adventure. You want to do a shout out too? Yeah, Ruth. Ruth, happy birthday. So Ford and GM on April 9th had an outside day. They call it an outside reversal day. So a higher high, a lower low than the previous day.

37:11Both of them have broken out. And I think you could probably take a look at the two of these. They've gotten such a headwind from tariffs and such a negative momentum. And I think that momentum is unwound. Well, Ford definitely. Something to say to Ruth? Yeah, well, look, I just hope Ruth has a great, great birthday. You know, her man was wearing blue. He was wearing the team colors, too, which is also great. Ford has been wearing the team colors. That's what they're telling you in these commercials. They're telling you, made in America, made in America. And Ford is certainly going to benefit more than GM.

37:40I mean, we're talking about$2 ,500 a vehicle roughly in terms of add-on costs versus$75 ,000 to$8 ,000 on a GM. I still think, Jim, is the far superior play with a lot of profitability to offset some of that. And not even just in advertising. I mean, just even from our own client base, the amount of people who have been looking at cars, and that is the sales pitch with car dealerships right now is buy now before the tariffs. I think you're going to see a lot of that pull forward. But I do think moving forward, the bigger thing is going to be where interest rates going, because of higher rates are going to mean it's higher to get these auto loans.

38:09And are consumers worried about the future? Because you just got those consumer sentiment numbers out, And people are more and more worried about what their future is going to look like and are going to put off those bigger purchases like auto. So I think that's going to be the bigger question when it comes to the auto industry. Coming up, you ask, we answer. Fast Money fans from across the country sending in their market questions where our traders stand on volatility, managing money through stormy waters and more. Those answers next. More Fast Money in two. Welcome back to Fast Money. Even with the recent rebound, lots of Fast Money viewers are still nervous about how to navigate the market swings.

38:41So let's get to a few questions sent in by fans who attended our last Fast Money Live event. Hey, Fast Money team. This is Bennett, the dairy farmer from Bakersfield, California. I had such a good time at the live event a while ago. Thanks so much for doing that. The cows are doing well, but my portfolio, not so much. So if I could, traders, please give me some advice. Should I raise some cash and try to get in at lower levels or should I just ride out the storm? Thanks so much. It's nice to hear from Bennett. It's nice to hear the cows are doing well. What would you recommend, Karen, in terms of cash and in and out and all that?

39:21Yes, obviously, I would recommend absolutely staying the course. It is nearly impossible to market time. I just, you know, you want to know you have companies with good balance sheets that they can ride out the storm. And then I would just do that, ride out the storm. Let's get to one more. Hi, Fast Money hosts. My name is Carol, and I bet some of you know exactly where I am in Washington, D.C. I have three children, age 19 through 26. When I was their age, I invested in technology mutual funds, which I still own. Where do you suggest the young adults today in this volatile market sock their extra cash?

40:01Well, Tim knew exactly where Carol was. I was like, holy cow, that's Georgetown. She's standing right in a hilly circle. Good for you, Carol. And good for you for getting the young investors out there. And that's in fact, that's really what we did at Fast Money Live. We talked about market volatility. We talked about long term plans. We didn't talk about trading in and out of the market. And I think we're probably going to have jittery markets for a while. But ultimately, how should you be investing for young people? Part of it should be you need to be diversified, but you need to be reaching for growth.

40:30I mean, ultimately, these are people that are going to be in the market through multiple cycles and frankly shouldn't really care over the short run. But, you know, buying, you know, just a high tech stock today that happens to be a fad. I would be careful about that. I would look more towards an ETF. Yeah. And especially for your young investors, you want to be diversified and even think about longer term. Like your small cap companies actually tend to outperform your larger companies, especially as younger investors. Thinking of something like your tax efficient strategies might actually work to think of like Roths and things like that might actually be really beneficial for your younger clients to look at.

41:00Well, if you want your questions answered by the Fast Money Traders, join us live for the next Fast Money Live event here at the NASDAQ. That's June 5th. Folks are coming from all over the country and even from down under Australia to join the party. So scan the QR code to your screen, on your screen, or head on over to cnbcevents.com slash fast money to grab your tickets. We're still counting down the days until June 5th because it's going to be a lot of fun. Up next, final trades. Time for the final trade. Tim Seymour. Okay, first of all, next Friday I want everybody showing up in, like, pistachio green.

41:30or like mint julep or something. Meanwhile, I'm going to show up with Tim's Pfizer. Karen. Right. I like Amazon. I think I like to be heard under Google last night for cloud. I think that'll be good for AWS, and I think they'll manage the tariffs well in their retailing business. Courtney. Apple. I would actually hold this year. I would not be buying into this yet. It still has a higher valuation. I think next week when we get earnings, they're still going to have a lot of headwinds, so I'd hang tight on this one. Stephen. After that outside reversal day on April 9th, You could either buy Ford or GM.

42:00I'm going to pick GM. All right. Thank you for watching Fast Money. Have a wonderful weekend. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, Internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

42:39To view the full Fast Money Disclaimer, please visit cnbc.com forward slash fast money disclaimer.

From the publisher

Stocks closing out a positive week, as tech stocks lead the market bounce with a big move off its recent lows. How our traders are positioning ahead of another big week of earnings, headlined by Apple, Microsoft, and Meta. Plus A major pharma fee. The $51 billion Trump’s tariffs could add to U.S. drug costs, and where one industry expert is still seeing opportunity in the space.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Stocks Wrap Up A Positive Week.. And How Pharma Will Fare Under Tariffs 4/25/25CNBC's "Fast Money" · 43 min
Listen in VO